Targeting the Inducible T-cell Costimulator (ICOS) in patients with Relapsed/Refractory T-Follicular Helper Phenotype Peripheral T-Cell and Angioimmunoblastic T-Cell Lymphoma.
Julio C ChavezFrancine M FossBasem M WilliamJonathan E BrammerSonali M SmithAnca PricaJasmine M ZainJoseph M TuscanoHarsh R ShahNeha Mehta-ShahPraveen Ramakrishnan Ramakrishnan GeethakumariBen X WangStephanie ZantingeLisa WangLing ZhangAnmarie BoutrinWeiguang ZhaoLily I ChengNathan StandiferLisa HewittEnowmpey EnowtambongWeiping ShaoShringi SharmaGianluca CarlessoJeffrey A MoscowLillian L SiuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
MEDI-570 was well tolerated and showed promising clinical activity in refractory AITL. MEDI-570 resulted in sustained reduction of ICOS+ T lymphocytes.